Skip to main content
. 2016 Feb 19;7:10759. doi: 10.1038/ncomms10759

Figure 2. In vivo blood pharmacokinetics and brain distribution of fusion protein in tg-ArcSwe and WT mice.

Figure 2

(a) The bispecific fusion protein (triangles, n=6) showed an increased half-life (11 h) compared with unmodified F(ab′)2-h158 (circles, n=3; 2 h). (b) The brain-to-blood concentration ratio of the fusion protein increased over time in tg-ArcSwe mice (>12 months, n=18) while remaining fairly constant in WT mice (n=14). (c) Comparison of brain distribution of fusion protein (n=7) and unmodified F(ab′)2-h158 (n=5) at respective Cmax. At this time point the increase in brain distribution mainly reflected increased transport across the BBB as the increase was observed both in tg-ArcSwe and WT mice (>18 months). (d) Comparison of brain distribution of fusion protein (n=10) and unmodified F(ab′)2-h158 (n=6) 72 h post injection. At this time point the differences observed between tg-ArcSwe and WT mice (>18 months) reflected binding to Aβ protofibrils. The symbols and error bars indicate group mean±s.d. from experiments (a). Each symbol represents one animal, line and error bars indicate group mean±s.d. (b–d). *P<0.05, ***P<0.001 and NS is nonsignificant by two-way analysis of variance followed by Bonferroni's post hoc test (b).